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1. Introduction
Living organisms are constantly exposed to pathogens. In any environment, a molec-
ular war begins when a host encounters a pathogen. In many hostepathogen associa-
tions, the molecular war is in progress a long time ago. Nevertheless, a disease as an
outcome of a pathogen attack remains an exception rather than a rule. Most host spe-
cies have acquired strategies by selective pressure to mislead the pathogen and to win
the fight during their cross talk (i.e., molecular dialogue). However, many pathogen
species have acquired strategies by selective pressure to bypass the host defenses to
win the molecular war and to ensure the completion of their life cycle. Pathogens
remain a significant threat to any host species. Critical to the mitigation of this threat
is the ability to rapidly detect, respond to, treat, and contain the pathogen transmission.
Since many centuries, some scientific fields (i.e., agroecology, evolutionary ecology,
evolutionary medicine, biochemistry, microbiology, medicine, veterinary medicine,
immunology, and molecular biology) have surveyed hosteparasite interactions to
improve our understanding of pathogenic diseases and to prevent pathogen transmis-
sion in host populations.
During the course of human history, pathogenic diseases have seriously affected
many societies worldwide. In Europe, one of the most dramatic disease events was
the great plague pandemic of the mid-14th century.1,2 Notably, pathogenic diseases
are a leading cause of premature death in the world. Pathogenic diseases result
from an intimate relationship between a host and a pathogen which involves molecular
“cross talk.” Clearly, elucidation of this complex molecular dialogue between host and
pathogen is desirable in order to improve our understanding of pathogen virulence, to
develop pathogen-specific host biomarkers, and to define novel therapeutic and vac-
cine targets. Proteomics applications to decipher hosteparasite interactions are in their
infancy in spite of important technological and scientific advances since the post-
genomic era, and should lead to new insights on host specificity and on the evolution
of pathogen virulence. In this chapter, we present the interest of proteomics to survey
hostepathogen interactions, a synthetic review of previous proteomics studies, the
pitfalls of the current approach in surveys, new conceptual approaches to decipher
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hosteparasite interactions, a new avenue to decipher the cross-talk diversity involved
in trophic interactions in a habitat (i.e., the population proteomics), and a 5-year view
for future prospects on proteomics and hostepathogen interactions.
2. Interest of Proteomics to Study HostePathogen
Interactions
Since the start of the genomic era in the early 1990s, many parasitologists and molec-
ular biologists are confident that complete sequencing of the genome of the partners in
hostepathogen associations for pathogens with simple life cycle (i.e., one host) and in
hostevectorepathogen associations for pathogens with complex life cycle (i.e., at
least two hosts) will enable the total understanding of the molecular mechanisms
involved in most of the pathogenic diseases and will contribute to find new drugs
for treating them3,4; insufficient progress has been achieved in the control of such dis-
eases as malaria and sleeping sickness, despite decades of intensive genomic projects
on hostepathogen interactions, vaccines, and chemotherapeutics. Pathogens continue
to be a major cause of morbidity and mortality in humans and domestic livestock, espe-
cially in developing countries.5e9
Until now, many parasitologists and molecular biologists have focused their studies
on DNA analyses based on the central dogma of molecular biologydthat is to say, the
general pathway for the expression of genetic information stored in DNA. Although
the basic blueprint of life is encoded in DNA, the execution of the genetic plan is car-
ried out by the activities of proteins. The fabric of biological diversity is therefore pro-
tein based, and natural selection acts at the protein level.10 At the end of the 20th
century, it had become clear to many parasitologists and molecular biologists that
knowing genome sequences, while technically mandatory, was not in itself enough
to fully understand complex biological events, such as the immune response of a
host to a pathogen infection or the molecular strategies used by pathogens to thwart
the host defenses during their interaction.11e15
The evolution of any given species has tremendously increased complexity at the
level of pre- (gene splicing, mRNA editing) and posttranslational (phosphorylation,
glycosylation, acetylation, and so on) geneeprotein interaction. The genomics era
has revealed that: (1) DNA sequences may be “fundamental,” but can provide little in-
formation on the dynamic processes within and between host and a parasite during
their physical and molecular interaction11,12; (2) the correlation between the expressed
“transcriptome” (i.e., total mRNA transcription pattern) and the levels of translated
proteins is poor16e18; and (3) a single gene can produce different protein prod-
ucts.13,14,18 Moreover, the structure, function, abundance, and even the number of
proteins in an organism cannot yet be predicted from the DNA sequence alone.11,17,19
Also, posttranslational modifications, such as phosphorylation and glycosylation, are
often extremely important for the function of many proteins, although most of these
modifications cannot yet be predicted from genomic or mRNA sequences.17 Thus,
the biological phenotype of an organism is not directly related to its genotype (i.e.,
DNA sequences).
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Epigenetic systems control and modify gene expression. Almost all the elements of
epigenetic control systems are proteins.19 The cells of an organism are reactive systems
in which information flows not only from genes to proteins but in the reverse direction
as well.3 The proteome is the genome operating system by which the cells of an organ-
ism react to environmental signals.19 It comprises an afferent arm, the cytosensorium
(i.e., many cellular proteins are sensors, receptors, and information transfer units from
environmental signals) and an efferent arm, the cytoeffectorium (i.e., in cells, reaction
of the genome via regulation of either individual proteins or a group of proteins in
response to environmental changes).
Proteomics is the study of the proteome. In a broad sense, the proteome (i.e., the
genome operating system) means all the proteins produced by a cell or tissue.
Proteomics will contribute to bridge the gap between our understanding of genome
sequence and cellular behavior. Proteomics offers an excellent way to study the reac-
tion of the host and pathogen proteomes (i.e., genome-operating systems) during their
complex biochemical cross talk.20,21 Using the first generation proteomics approach,
two-dimensional electrophoresis (2-DE), and mass spectrometry (MS), posttransla-
tional modifications of host and pathogen proteins (such as phosphorylation,
glycosylation, acetylation, and methylation) in reaction to their interaction can be
detected. Such modifications are vital for the correct activity of numerous proteins
and are being increasingly recognized as a major mechanism in cellular regulation.
Although 2-DE offers a high-quality approach for the study of host and/or pathogen
proteomes, during the post-genomic era several proteomics approaches (e.g.,
bottom-up; top-down) and quantitative proteomics strategies have been developed,
which complement classical 2-DE (see Fig. 11.1).17,22e26 Table 11.1 presents a com-
parison of the most popular proteomics tools.
3. Retrospective Analysis of Previous Proteomics
Studies
The hostepathogen cross talks reflect the balance of host defenses and pathogen viru-
lence mechanisms. Post-genomic technology promises to revolutionize many fields in
biology by providing enormous amounts of genetic data from model and nonmodel
organisms. Proteomics is a case point and promises to bridge the gap between our un-
derstanding of genome sequences and cellular behavior involved in hostepathogen in-
teractions. Proteomics offers the possibility to characterize hostepathogen interactions
from a global proteomic view. To date, most proteomics surveys on hosteparasite in-
teractions have focused on cataloguing protein content of pathogens and identifying
virulence-associated proteins or proteomic alterations in host response to a pathogen.
Also, many parasitologists and molecular biologists have used proteomics to find
pathogen-specific host biomarkers for rapid pathogen detection and characterization
of hostepathogen cross talks during the infection process. In this section, a synthetic
retrospective of previous proteomics studies on hostepathogen interactions and some
pitfalls of these surveys are presented.
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Figure 11.1 Deciphering of hosteparasite cross talk with proteomics. Bottom-up and Top-
down approaches (A); and quantitative proteomics strategies (B).
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Table 11.1 A Comparison of Proteomics Tools
Name of
Technique Separation Quantification
Identification of
Candidate Protein
Spots
Hydrophobic
Proteins
Requirement
for Protein
Identification
Potential for
Discovering
New
Proteins
Detection
of Specific
Isoforms
Relative
Assay
Time
Cost to
Acquire
and to
Use
2-DE Electrophoresis:
IEF PAGE
Densitometry of stains Mass spectrometry
(PMF; MS/MS)
Dependent on
detergents used
No Yes Yes Moderate Cheap
2-DIGE Electrophoresis:
IEF PAGE
Densitometry of Cy3- and
Cy5-labeled proteins
normalize to Cy2
Mass spectrometry
(PMF; MS/MS)
Dependent on
detergents used
No Yes Yes Moderate Expensive
MuDPIT LCeLC of
peptides
None Mass spectrometry
(MS/MS)
Theoretically better
than
electrophoresis but
not systematically
examined
No Yes Yes Rapid Moderate
ICATTM LC of peptides Through use of heavy and
light tags
Mass spectrometry
(MS/MS)
No better than 2-DE No Yes No Rapid Moderate
iTRAQ LC of peptides Labeling with isobaric
mass tags
Mass spectrometry
(MS/MS)
No better than 2-DE No Yes Yes Rapid Expensive
SILAC LC of peptides Metabolic labeling with
enriched stable isotope
of amino acids
([13C6
15N4]arginine and/
or [13C6
15N2] lysine).
Mass spectrometry
(MS/MS)
No better than 2-DE No Yes Yes Rapid Moderate
Continued
Table 11.1 A Comparison of Proteomics Toolsdcont’d
Name of
Technique Separation Quantification
Identification of
Candidate Protein
Spots
Hydrophobic
Proteins
Requirement
for Protein
Identification
Potential for
Discovering
New
Proteins
Detection
of Specific
Isoforms
Relative
Assay
Time
Cost to
Acquire
and to
Use
SELDI-
TOF
MS
Binding of
proteins based
on their
chemical and
physical
characteristics
Comparison of MS peaks Requires series of
samples or
coupling to
second MS
instrument
Moderate No Yes No Rapid Expensive
Protein
arrays
Antibody-based
chips (binding
to affinity
reagent)
Densitometry of binding Binding to
particular
affinity reagent
Unknown Yes No Yes Rapid Cheap
2-DE, two-dimensional electrophoresis; 2-DIGE, two-dimensional difference in gel electrophoresis; ICAT, isotope coded affinity tags; iTRAQ, isobaric tag for relative and absolute quantification; LC, liquid
chromatography; LCeLC, tandem liquid chromatography; MS/MS, tandem mass spectrometry; MuDPIT, multidimensional protein identification technology; PAGE, polyacrylamide gel electrophoresis; PMF,
peptide mass fingerprint; SELDI-TOF MS, spectrum enhanced laser desorption ionization-time of flight mass spectrometry; SILAC, stable isotope labeling by amino acids in cell culture.
3.1 Deciphering of the Molecular Strategies Involved in Parasite
Immune Evasion
To elude the vigilance of the immune system of a host, particularly mammals, a caus-
ative microorganism must actually act as a double agent. Indeed, the broad immunity
has a natural or innate and adaptive component. Innate immunity constitutes the first
antimicrobial defense and rapidly induces soluble mediators, such as complement, in-
flammatory cytokines, and chemokines, together with effector cells, such as macro-
phages and natural killers, in order to control or delay the spreading of the
infectious agent. Then a specific response of adaptive immunity will take place to elim-
inate pathogens that would have survived innate immune response.27 These immune
selective pressures have conducted pathogens to develop mechanisms to modulate
and alter host responses or to evade phagocytosis. As a result of these hostepathogen
interactions, protein expression profiles of the host immune system (susceptibility/
tolerance factors) and of the pathogen (virulence/pathogenicity factors) are mutually
modified.28e30
Depending on the pathogen type (virus, bacteria, fungi, and unicellular or multicel-
lular parasites), strategies of interactions will be different and the subversion of the
host immune responses will exhibit specificities at the protein level (for reviews see
Refs. 20,31,32). In fact, these molecular dialogues and conflicts can be seen as a chess
game between the host immune cell populations and the pathogen populations, in
which the pathogen plays with the whites (i.e., it starts the game). Because of differ-
ences in hostepathogen organisms’ size and ratio, leading to size differences of
respective proteomes, the pathogen proteome could be considered as overwhelmed
by the host proteome during the interactions. But in terms of immune evasion, this
is not limiting because the immune system works on a qualitative basis, which consti-
tutes a second advantage for the pathogen that can induce large-scale damages with
low amounts of molecules. By contrast, this represents not only one major limitation
to characterize hostepathogen interactions, but also a challenging perspective for pro-
teomics technology. This is why retrospectively proteomics studies were mainly con-
ducted to evidence pathogenic virulence and pathogenicity factors.33e43
Independent of the proteomics workflow used for analysis, parasite immune
evasion could be illustrated by at least three strategies that are commonly widespread
among pathogens: (1) immune evasion based on antigenic variation, (2) inhibition of
adaptive immunity activation systems, and (3) host mimicry. In African trypanosomes,
the antigenic variation of the variant surface glycoprotein (VSG) constituting the sur-
face coat of the parasite is well described.44 But as in proteomics study, the parasite
population, which has switched the VSG, is so poorly represented that it goes unde-
tected, and therefore always keeps one step ahead of host immune responses. Also
in trypanosomatids, Leishmania amastigotes, which establish within macrophage (a
major immune effector cell), developed the ability to degrade class II major histocom-
patibility molecules to prevent Th1-type immunity to be induced.45 Another protozoan
parasite, Toxoplasma gondii, generates its parasitophorous vacuole with elements of
the plasma membrane from the targeted host cells, thus using the host “self” to evade
immune recognition.46 These few examples actually perfectly illustrate how difficult it
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is to decipher, at the protein level during interactions, the pathogen molecular compo-
nents involved in immune evasion. However, a new quantitative proteomics tools, the
SILAC (stable isotope labeling by amino acids in cell culture) lately allowed the detec-
tion of 148 proteins of a microsporidian parasite during the kinetics of a host infec-
tion.47 Among these proteins, many are involved in parasite proliferation, and an
overrepresentation of putative secreted effectors proteins was observed. Finally, this
SILAC survey also suggests that this microsporidia species could use a transposable
element as a lure strategy to escape the host innate immune system. Advances in pro-
teomics offer challenging perspectives to decipher the molecular war in hoste
pathogen interactions.26
3.2 Host Proteome Responses to Parasite Infection
While it seems obvious to say that when a pathogen will infect a host, the later will
react by expressing molecules that can be characterized by clinical proteomics, it is
surprising how few studies are devoted to this research. Yet the discovery of bio-
markers signing an infected state from a healthy state is the heart of the Infectious Dis-
ease Research,48,49 and expression proteomics has quickly developed to characterize
the differential expression of proteins encoded by a particular gene and their posttrans-
lational modifications in biological fluids and tissues.50e52 In characterizing the host
proteome responses to a pathogen infection, different levels of analysis have to be
considered: soluble biomarkers expressed in biological fluids (e.g., serum, saliva,
urine, and cerebrospinal fluid), tissue biomarkers indicative of an organ response
and cellular biomarkers indicative of a cell-type response (e.g., immune cells).
Interestingly, the majority of the proteomics studies on host response to infection
were performed on viral deregulation of host cells proteome ex vivo.53e61 These works
allowed to characterize at the molecular level the overall modifications in protein pro-
files of the target cells, and were of high interest to the better understanding of the path-
ogen influence on its host. In bacteria, studies have evaluated the mode of action of
known toxins or bacterial components on host cells.62,63 Concerning parasites,
ex vivo experiments on hosteparasite interactions have highlighted molecular details
of manipulation strategies suffered by target cells during toxoplasmosis Chagas’ dis-
ease or malaria.64e66 Curiously, few works directly focused on the subversion of the
immune system, mainly through monocyte/macrophage deregulation.67,68
As a paradox, the most striking studies on host proteome response to parasite infec-
tion were performed on arthropod (infectious diseases vectors)eparasite interactions.
Probably because the parasite induced a strong phenotype modification,69,70 particu-
larly in the case of insect behavior manipulation.71,72 Although few in number, taken
together, these pioneering analyses of the response of the proteome of the host to a
pathogen pave the way for the dynamic analysis of hostepathogen interactions. These
approaches deserve to be strengthened and extended to all infectious diseases to in-
crease and improve knowledge of the molecular dialogue and conflict that govern
hostepathogen interactions.
On the other hand, the clinical aspect is important in infectious diseases, a num-
ber of studies have sought to characterize more comprehensively the proteome
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response of the host to infection in biological fluids, with a purpose diagnosis. One
interesting pioneering study was performed in rabbits and allowed to detect intra-
amniotic infection by proteomic-based amniotic fluid analysis.73 For human dis-
eases or those of livestock, the biological fluid, which should enable the detection
of infection, linked to host proteome response, in the host serum. Several studies
performed on this biological sample have allowed discriminating host-commensal
from hostepathogen interactions in Candida albicans74 and determining the immu-
nome of pathogens.75,76 Moreover, in African trypanosomiasis, proteomics analysis
of the serum not only was indicative of the host response to infection, but also was
promising for characterizing disease progression toward neurological disorder.77,78
This illustrates how proteomics will help in considering at different analytical levels
the host proteome response to a pathogen infection, with the prospect of benefits in
improving diagnostics and therapeutics.
3.3 Biomarkers Linked to Infection Process by a Pathogen Using
SELDI-TOF-MS Technology
High-throughput proteomic technology offers promise for the discovery of disease
biomarkers and have extended our ability to unravel proteomes. In this section, we
focus on the Surface-enhanced laser desorption time of flight mass spectrometry
(SELDI-TOF-MS) technology. This MS-based method requires a minimal amount
of sample for analysis and allows the rapid high-throughput analysis of complex pro-
tein samples.79 SELDI-TOF-MS differs from conventional matrixeassisted laser
desorption ionization (MALDI)-TOF-MS because the target surfaces, to which the
proteins and matrices are applied to, are coated with various chemically active Protein-
Chip surfaces (ion exchange, immobilized metal affinity capture, and reverse phase ar-
rays). Therefore, it is possible to fractionate proteins within a mixture, or particular
classes of proteins, on the array surface prior to analysis. As with MALDI, different
matrices can be used to facilitate the ionization and desorption of proteins from the
SELDI array surface.80
This technology was initially applied to the discovery of early diagnostic or prog-
nostic biomarkers of cancer.81e83 Subsequently, this technology was used to discover
fluid or tissue protein biomarkers for infectious diseases, such as HIV-1,84e89
hepatitis B and C viruses,66,90e93 severe acute respiratory syndrome94 and BK virus,95
African trypanosomiasis,78,96 infection of Artemia by cestodes,97 tuberculosis,98
bacterial endocarditis,99 and Helicobacter pylori infection.100
Certain individuals are resistant to HIV-1 infection, despite repeated exposure to the
virus. The analysis of resistance to HIV infection is one of the research avenues, which
has the hope of resulting in the development of a more effective treatment or a success-
ful preventive vaccine against HIV infection. However, the molecular mechanism un-
derlying resistance in repeatedly HIV-1-exposed, uninfected individuals (EU) is
unclear. A complementary transcriptome and SELDI-TOF-MS analyses have been
performed on peripheral blood T cells, plasma or serum from EU, their HIV-1-
infected sexual partners, and healthy controls.86 This study detected a specific
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biomarker associated with innate host resistance to HIV infection, as an 8.6-kDa A-
SAA cleavage product.
In the same vein, understanding the virusehost interactions that lead to patients
with acute hepatitis C virus (HCV) infection to viral clearance is a key toward the
development of more effective treatment and prevention strategies. SELDI-TOF-MS
technology has been used to compare, at a proteomic level, plasma samples, respec-
tively, from donors who had resolved their HCV infection after seroconversion,
from donors with chronic HCV infection, and from unexposed healthy donors.92 A
candidate marker of about 9.4 kDa was found to be higher in donors with HCV clear-
ance than in donors with chronic infection. This biomarker was identified by nanoLC-
Q-TOF-MS/MS as Apolipoprotein C-III and validated by Western Blot analysis.
Among the most strongly upregulated genes in Dengue viruseinfected Aedes aegypti
salivary glands, one study identified a gene belonging to the cecropin family. The over-
expression of this antimicrobial peptide was confirmed using the SELDI-TOF-MS
technique.101
4. Toward New Conceptual Approaches to Decipher the
HosteParasite Interactions for Parasites With Simple
or Complex Life Cycle
One main goal of “parasite-proteomics” surveys is to find proteins for use as pathogen-
specific host biomarkers and to decipher the hostepathogen cross talks. Some papers
emphasize that a significant number of surveys were done with a nonrigorous exper-
imental design and without a conceptual approach to disentangle a general host prote-
ome response from a specific host proteome response during the interaction with a
pathogen.12,20,30,43,102 A new attitude is essential to improve the reliability of prote-
omics data on hostepathogen interactions. Lately, some conceptual approaches
have been proposed to researchers working on hostepathogen interactions to improve
the reliability of “parasite-proteomics” results and to stimulate the creation of proteo-
mic database with a holistic view of hostepathogen interactions. Thus, in this section,
three new avenues to decipher hostepathogen interactions for any pathogen species
(i.e., with simple or complex life cycle) are presented.
4.1 A Holistic Approach to Disentangle the Host and Parasite
Genome Responses During Their Interactions
Some proteomics studies have shown common features in the innate response of
plants, insects, and mammals.103e106 The plant defense response is mediated by
disease-resistance genes (R genes), which are abundant throughout the genome and
confer resistance to many microorganisms, nematodes, and/or insects. R genes of
several families of plants studied to date show homology with the Drosophila receptor
Toll and the mammalian interleukin-1 receptor. In addition, plants, invertebrates, and
vertebrates produce a class of peptides called “defensins,” which are
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pathogen-inducible.103 Some peptides and/or proteins used by phytophagous or ani-
mal parasites to modify the genome expression of their host share many structural
and functional homologies. Thus, for example, phytoparasitic root-knot nematodes
of the genus Meloidogyne secrete substances into their plant hosts in order to make
a giant cell used as a feeding site.107,108 A similar system is observed for the zoopara-
site, Trichinella spiralis (Stichosomida: Trichinellidae).109 Furthermore, the injection
of a peptide isolated from nematode secretions to either plant protoplasts or human
cells enhances cell division.110 The mechanism is not yet well known, but protein in-
duction is considered as a strong possibility.
These days, many data are obtained by genomic and proteomics projects concerned
with hosteparasite interactions. Nevertheless, as mentioned earlier, generally little
effort is made to elaborate such projects with respect to a holistic view of the goal
to increase knowledge concerning immune responses of a host along with the
biochemical cross talk between host and pathogen/parasite. Thus far, “parasito-
proteomics” studies are in their infancy but have already led to new insights concern-
ing molecular pathogenesis and microorganism identification.111,112 However, many
“parasito-proteomics” studies have been done with powerful tools, but without a con-
ceptual approach to disentangle the host and parasite genome responses during their
interactions.
Lately, a new holistic approach was proposed to parasitologists and molecular bi-
ologists based on evolutionary concepts of the immune response of a host to an
invading parasite (for more details see Ref. 20). For instance, this new conceptual
approach enables the classification of the host genomic response to infection by a para-
site according to the immune mechanisms used (constitutive versus induced) and the
degree of specificity. From an evolutionary-ecological point of view, host immune re-
sponses to a particular parasite can be plotted on a chart according to the immune
mechanisms used (constitutive versus induced) and degree of specificity. The first
axis of the defense chart refers to the immune mechanisms employed by the host
with the two extreme cases: (1) a constitutive immune mechanism used by the host
to rapidly impair the invasion by a parasite and (2) an induced immune mechanism,
which has the advantage of avoiding a costly defense system, yet has the disadvantage
that the parasite might escape host control.15 The second axis of the defense chart re-
fers to the degree of specificity of the host immune response.
Whatever the tactics used and the degree of specificity, the host genome ensures the
adequate operation of the immune response via the proteome (genome operating sys-
tem). For each immune tactic, many proteins are implicated. Consequently, any
researcher in parasito-proteomics working with the immune defense chart will be
able to categorize the host genome reaction for any given parasite at any given
time. Also, for the pathogen, from an evolutionary-ecological point of view, parasite
molecular strategies used to counteract host immune system can be plotted on a chart
according to the infection mechanisms used (constitutive versus induced) and degree
of specificity. This type of approach should be as much hypothesis generating for
parasito-proteomics as for evolutionary ecology itself.
Lately, pioneer proteomics studies on parasite-induced alteration of host behavior
(widespread transmission strategy among pathogens) have been carried out on six
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arthropod hosteparasite associations: two orthopteraehairworm associations, two in-
sect vectorepathogen associations, and two gammarideparasite associations.113
These “parasito-proteomics” studies were based on the conceptual approach suggested
by Biron et al.20,21 Thus, in each study, many biological treatments have been effected
to control the potential confusion resulting from proteins that are nonspecific to the
manipulative process and to find the protein potentially linked with host behavioral
changes. Also, for each study, to limit the possible effects of multiple infection and/
or host sex-specific factors on the host proteome response, only monoinfected host
males were used for the proteomics analysis. These “parasito-proteomics” surveys
on the parasitic manipulation hypothesis showed that proteomic tools and the concep-
tual approach suggested by Biron et al.20,21 are sensitive enough to disentangle host
proteome alterations, and also the parasite proteome alterations linked to many factors,
such as the circadian cycle, the parasitic status, parasitic emergence, the quality of a
habitat, and the manipulative process.
4.2 Pathogeno-Proteomics: A New Avenue to Decipher
HosteVectorePathogen Interactions
Relationships between pathogens and their hosts and vectors depend on a molecular
dialogue tightly regulated. The reciprocal influence of a pathogen with its host or vec-
tor will affect the level of their genomes and their expression, respectively.30 Vari-
ability and cross-regulation increase from genomic DNA (mutations, rearrangement,
methylations, and so on) through RNA transcripts (initiation, splicing, maturation,
editing, stability, and so on) to functional proteins (initiation, folding, posttranslational
modifications, localization, function, and so on). Pathogeno-proteomics is a new
approach to decipher hostevectorepathogen interactions, which integrates modifica-
tions at all analytical levels (genome, transcriptome, proteome: whole cell content, and
secretome: naturally excretedesecreted molecules) through the analysis of their end-
products’ profile (Fig. 11.2). The concept is based on a management with drawers
Figure 11.2 Pathogeno-proteomics: integrating analytical levels in hostevectorepathogen
interactions.
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of the analytic workflow, from the determination of number of experimental treatments
and design of the biological material preparation to the dedicated proteomics and bio-
informatics tools needed to answer a research question in cell immunobiology (directly
involved in hostepathogen interactions (Fig. 11.3)) but also in ecology and evolution,
population’s biology, and adaptive processes.10,30,114 Moreover, it has been proved
that the results of this type of integrated approach has a concrete impact on the discov-
ery of the causes of infectious diseases, as well as on improving the diagnosis, vaccine
development, and rational drug design.115e117 Despite a theoretical aspect,118 the
pathogeno-proteomics concept brought new insights into important aspects of cell
signaling119 and molecular medicine.120,121 As an example, proteomics and bioinfor-
matics tools enable the formulation of relevant biological hypothesis on why part of
the fungal population is killed while a significantly high percentage survives in
C. albicansemacrophage interactions,122 leading to addition of a specific database
for studying C. albicansehost interactions.123 Direct applications in terms of discov-
ery of antifungal drug targets or design of new effective antibacterial vaccines become
reality.40,124 Other studies have also highlighted the pathogenic changes in the brain of
SIV-infected monkeys,125 adaptive metabolic changes in Trypanosoma cruzi and Try-
panosoma congolense,126,127 or molecular biomarkers of intestinal disorder induced
byH. pylori or Tritrichomonas muris.100,128 Subsequently, the use of model organisms
interacting with infectious agent of medical importance emphasized the complexity
and pathogen specificity of the worm’s immune response.129 Taken together, these ex-
amples demonstrate the potential of the concept of pathogeno-proteomics and promote
this new research avenue.
Figure 11.3 A new biological entity named hostepathogen interactome corresponding to
complete set of proteineprotein interactions existing between all the proteins of a host and a
pathogen during their interaction.
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5. Population Proteomics: An Emerging Discipline to
Study HosteParasite Interactions
The host susceptibility to a pathogen and/or the pathogen virulence are often fluctu-
ating within a host population even when infected hosts are collected in the same
habitat and at the same time. This host phenotypic variability can be caused by three
factors: (1) host genotype and/or pathogen genotype, (2) different environmental ex-
periences (e.g., habitat fragmented in microclimates), and (3) host coinfection by path-
ogens (i.e., competition or mutualism among coinfecting pathogens within hosts).
What are the hostepathogen cross talks at individual and population scales in a
habitat? Is it possible to detect and to decipher the host proteome variability within
a habitat for the molecular mechanisms and for the protein networks involved in the
hostepathogen interactions? In this section, a new emerging discipline in proteomics,
the population proteomics, and its prospects are presented with results of some pioneer
studies on this topic, especially in human population proteomics.
5.1 Prospects With Population Proteomics for Any Living
Organisms
One limiting factor for the first generation of proteomics tools (e.g., 2-DE) is the
amount of proteins required to study the host and/or pathogen proteome expression(s)
during their interactions. Most surveys in “parasite-proteomics” were done by pooling
many individuals for any treatment (e.g., infected and noninfected hosts) required to
answer a query. Thus, with this kind of experimental protocol, no data can be acquired
on the interindividual variation in expression of host and pathogen proteomes during
their cross talk. New proteomics tools and methods have been developed as 2D-LC/
MS that can permit to study the interindividual variation of molecular cross talk in
hostepathogen associations.130e132
At the beginning of the century, Dobrin Nedelkov proposed a new scientific field in
proteomics: the population proteomics.130 Population proteomics was defined as the
study of protein diversity in human populations, or more specifically, targeted inves-
tigation of human proteins across and within populations to define and understand pro-
tein diversity with the main aim to discover disease-specific protein modulations.133
Biron et al.114 have proposed to broaden the “population proteomics” concept to all
living organisms with the aims to complement the population genetics and to offer a
new avenue to decipher the cross talk diversity involved in trophic interactions in a
habitat since the execution of the genetic plan is carried out by the activities of proteins
and natural selection acts at the protein level.10,134
The apparent separation between genomics and proteomics that leads to different
perspective on the same ecological reality is a fundamental limitation that needs to
be overcome if complex processes, such as adaptation, pathogen virulence, and host
susceptibility, are to be understood. Population proteomics coupled with population
genetics has a great potential to resolve issues specific to the ecology, the evolution
of natural populations, the dynamic of host susceptibility to pathogens, the evolution
of pathogen virulence, and the range of host genotypes that can be infected with a
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given pathogen genotype in hosteparasite interactions. Some perspectives for the pop-
ulation proteomics are resumed in Fig. 11.4. Even if we are yet far from this “promised
land,” a better understanding of the information contained in proteomics markers
should permit an impressive amount of information to be gathered on the past as
well as current environmental conditions experienced by a given population of a spe-
cies, something that could be summarized as “show me your proteome and I will tell
you who you are, where you are from, and where you should go from here.”
Lately, pioneer surveys on population proteomics have been carried out with clas-
sical proteomic tools (i.e., 2-DE and MS) (1) to determine the genetic variability be-
tween species and between populations of a given species,135e137 (2) to identify
biochemical signatures linked to particular habitat and/or environmental condi-
tions,138,139 and (3) for phylogenetic studies.130,140 Nedelkov et al.141,142 have inves-
tigated the human plasma proteins diversity by using approaches similar to enzyme-
linked immunosorbent assay but utilizing MS as method of detection.133 These pioneer
results should help not only to discover disease-specific protein modulations but also
to find pathogen-specific protein biomarkers. The next subsection presents in detail the
Nedelkov’ results on protein diversity in human populations.
5.2 Human Population Proteomics
Human population proteomics deciphers protein diversity in human populations. In a
broader term, human population proteomics can be compared to human population ge-
nomics, where individuals are interrogated with the aim of cataloguing common
Prospects in population proteomics
Fundamental Applied
-Deciphering of inter-individual variation in
expression of host and pathogen proteomes
during their interactions in a habitat.
-Discovery of disease-specific protein
modulations.
-Identification of biochemical signatures
linked to particular habitat and/or
environmental conditions.
-Development of biomakers as “stress 
indicators” to help in the conservation of
habitats.
-Phylogenetic studies of immune proteins
to develop new drugs and vaccines.
-Measurement of genetic variation within
and between population(s) of a given 
species.
-Estimation of fitness differences between
gene and genotypes of a given species.
-Taxonomic, phylogentic and cladistic
studies.
Figure 11.4 Potential of population proteomics as an emerging discipline in proteomics.
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genetic variants and determining how they are distributed among people within pop-
ulations and among populations in different parts of the world.143e145 Although hu-
man population proteomics cannot (yet) claim such outreach and goals, it has the
potential to become an important proteomics subdiscipline as the tools and approaches
that enable it become more embraced and practiced.
Human population proteomics does not engage the study of entire proteomes
because it is very likely that, for a specific cell or tissue proteome, there is no definitive
set and number of proteins that is common to all within a group or a larger population.
Instead, human population proteomics focuses on interrogation of a selected number of
proteins but from a large number of individuals, to delineate the distribution of specific
protein modifications within these subpopulations. Hence, targeted protein analysis
approaches utilizing MS as detection method are employed. MS measures a unique
feature of each fully expressed proteindits molecular mass. Changes in the protein
structure resulting from structural modifications are reflected in its molecular mass
and can be detected via MS, without a priori knowledge of the modification. The
MS methods utilized in human population proteomics must be capable of analyzing
hundreds, if not thousands of samples per day, with high reproducibility and sensi-
tivity. Hence, top-down MS approaches utilizing affinity ligands are the most likely
methods of choice for population proteomics.144 Surface-immobilized ligands can
be utilized to affinity-retrieve a protein of interest from a biological sample, after which
the protein (with or without the affinity ligand) is introduced into a mass spectrometer.
One of the first affinity MS methods developed was mass spectrometric immunoassay
(MSIA).146 The approach combines targeted protein affinity-extraction with rigorous
characterization using MALDI-TOF MS (Fig. 11.5). Protein(s) are extracted from a
biological sample with the help of affinity pipettes derivatized with polyclonal anti-
bodies. The proteins are eluted from the affinity pipettes with a MALDI matrix, and
are MS-analyzed. Enzymatic digestion, if needed, is performed on the MALDI target
itself. Specificity and sensitivity, as in traditional immunoassays, are dictated by the
affinity-capture reagentsdthe antibodies.
However, a second measure of specificity is incorporated in the resulting mass
spectra, wherein each protein registers at specific m/z value. During data analysis,
the major signal in the mass spectrum that corresponds to the targeted protein is
initially evaluated; it should be within a reasonable range (e.g., error of measurement
of <0.05%) from the value of the empirically calculated mass obtained from the
sequence of the protein deposited in the Swiss-Prot databank. Once this mass value
is confirmed (or observed to be shifted), the presence of protein modifications is noted
by the appearance of other signals in the mass spectra (usually in the vicinity of the
native protein peaks), or by mass shifts of the major protein signal. Modifications
can be tentatively assigned by accurate measurement of the observed mass shifts
(from the wild-type protein signals and/or in silico calculated mass) and knowledge
of the protein sequence and possible modifications. The identity of the modifications
is then verified using proteolytic digestion and mass mapping approaches in combina-
tion with high-performance MS.
In an initial study of human protein diversity using MS methods of detection, 25
plasma proteins from a cohort of 96 healthy individuals were investigated via MS
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immunoassays.147 The protocol and an example of the data generated for one of the
proteins, transthyretin (TTR), are outlined in Fig. 11.6. The TTR MSIA assays were
performed in parallel on the 96 human plasma samples using affinity pipettes derivat-
ized with anti-TTR antibody. Following MS analysis, data matrix containing all tenta-
tively assigned modifications was assembled. Then, peptide-mapping experiments
were performed on selected number of samples to identify the specific modifications
and finalize the modifications database. The data for all 25 proteins is presented in
Fig. 11.7, which lists the modifications observed for 18 of the 25 proteins studied
(modifications were not observed for 7 proteins), and shows the frequency of each
modification in the 96 samples cohort. A total of 53 protein variants were observed
for these 18 proteins, stemming from posttranslational modifications and point muta-
tions. The largest number of posttranslationally modified protein variants was found to
be C- or N-terminal truncated protein isoforms. Deglycosylation, oxidation, and cys-
teinylation were also observed among several of the proteins. Among the point muta-
tions detected for four of the proteins, notable was the high incidence of point
mutations for apolipoprotein E and TTR, which is consistent with genomic studies
that have found these proteins to be highly polymorphic. The overall frequency of
Figure 11.5 Schematics of the mass spectrometric immunoassay (MSIA) approach.
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Figure 11.6 An outline of a population proteomics approach using TTR as an example. m/z,
mass-to-charge ratio; TTR, transthyretin.
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the modifications in the 96 samples cohort was wide ranged. Fourteen modifications
were observed in all 96 samples, suggesting that they must be regarded as wild-type
protein forms. Others, such as most of the point mutations, were present in only few
of the samples. Overall, 23 of the modifications were observed in more than 65% of
the samples, and 20 in less than 15% of the 96 samples analyzed. Upon further data
analysis, and taking into the consideration the gender, age, and ethnicity of the
Figure 11.7 Modifications observed in 18 of the 25 proteins analyzed from 96 human plasma
samples.
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individuals who provided the samples, it was determined that the Gly6Ser mutation in
TTR was detected only in individuals of Caucasian origin, which is consistent with
existing knowledge about the occurrence of this common non-amyloidogenic popula-
tion polymorphism in Caucasians.148,149 Another correlation was observed in regard to
interprotein variations in specific individuals: all seven individuals for which
carbohydrate-deficient transferrin was detected were also characterized with deglyco-
sylated antithrombin III.
Following this small-scale protein diversity study, a second study of human protein
diversity was carried out wherein the number of samples was greatly expanded in order
to get an accurate view of the distribution of some of the protein modifications in the
general population.142 Thousand individuals from four geographical regions in the
United States (California, Florida, Tennessee, and Texas) were selected, and the pro-
tein modifications for beta-2-microglobulin (b2m), cystatin C (cysC), retinol-binding
protein (RBP), transferrin (TRFE), and TTR were delineated (in the 96 samples study,
these five proteins accounted for 19 of the 53 protein variants observed). The results of
the study are summarized in Fig. 11.8, which lists the protein modifications observed
and the frequency of each in the 1000 samples cohort. A total of 27 protein modifica-
tions (20 posttranslational modifications and 7 point mutations) were detected, with
various frequencies in the cohort of samples. Variants resulting from oxidation were
observed most frequently, along with single amino acid truncations. Least frequent
were variants arising from point mutations and extensive sequence truncations. In
total, 6 modifications were observed with high frequency (present in >80% of the
samples), 5 were of medium frequency (20e50% of the samples), and 16 were
low-frequency modifications observed in <7% of the samples. Nine of the
low-frequency modifications were not observed in the 96 individuals study. Thus,
by increasing the size of the population, it became possible to detect these low-
occurrence protein modifications. When the frequencies of the modifications in the
two studies were compared, an excellent correlation was obtained. For example, in
both cohorts about 7% of the individuals were characterized with carbohydrate-
deficient transferrin. Upon further data analysis based on the gender, age, and
geographical origin of the individuals who provided the samples, it was determined
that the samples obtained from California contained significantly less protein modifi-
cations than the samples obtained from Florida, Tennessee, and Texas, even though the
samples from all four states were collected in the same way within a 3-month window
in the spring of 2005, and stored under identical conditions until analysis. Correlations
were also made in regard to the gender distribution of two protein modifications.
Carbohydrate-deficient transferrin was observed in about 1% of the females and about
10% of the males in the 1000 cohort. Carbohydrate-deficient transferrin is an FDA-
approved clinical biomarker for alcoholism, and this gender correlation can partially
be explained by the higher prevalence of alcohol dependence in males than in females.
The second gender correlation was related to cystatin C: all 10 of the cystatin C point
mutations were found in males.
Two conclusions can be made from these two systematic studies of protein modi-
fications and variants. First, MS is capable of detecting structural protein modifica-
tions, and, when coupled to immunoaffinity separations, it can be employed in a
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high-throughput systematic study of human protein diversity. Second, the human pro-
tein diversity is far more complex than the variation observed at the genetic level.
While it might be premature to declare the human proteins variation “the next big
thing,” it is reasonable to predict that assessing human proteome variations among
and within populations will be a paramount effort that can facilitate biomarker discov-
ery. Such endeavor would represent a paradigm shift in proteomics with significant
clinical and diagnostic implications, as protein variations, quantitative and qualitative,
begin to be associated with specific diseases.
6. Conclusion
From the dawn of human evolution to the influenza and HIV/AIDS pandemics of
the 20th and early 21st centuries, infectious diseases have continued to emerge and
re-emerge with great ferocity and, by so doing, seriously affect populations as well
as challenge our abilities to fight the responsible agents. Over the past decade, strains
of many common pathogens have continued to develop resistance to the drugs that
Figure 11.8 Modifications observed for five proteins studied from 1000 human plasma
samples.
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once were effective against them. In the battle against pathogens, humankind has
created new mega-technologies, such as massive sequencing, proteomics, and bioin-
formatics, but without conceptual approaches based on the evolutionary concepts.
Parasite genome sequences do not of themselves provide a full explanation of the
biology of an organism and on the molecular war involved in hostepathogen associ-
ations. Since the 1990s, proteomic tools have been successfully employed in a large
number of studies to find and identify proteins involved in biological phenomena,
for example, immunity, hosteparasite interactions, and so on. Even so, many studies
have, as outlined earlier, revealed pitfalls in the approaches used. Thus, whatever the
new technological advancements, it is apparent that parasitologists and molecular bi-
ologists should attempt to improve their experimental design. This new attitude will
surely improve the reliability of the data deriving from proteomics studies and will
open the way for an enhanced comprehension of many biological mechanisms. In
this chapter, new ways based on evolutionary concepts are suggested to enable further
elucidation of the molecular complexities of hostepathogen genome interactions.
These new ways could help to increase the knowledge about the molecular war
involved in hostepathogen associations taking into account the environmental factors.
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